| BCR-ABL1 compound mutations combining key kinase domain positions confer clinical resistance to ponatinib in Ph chromosome-positive leukemia MS Zabriskie, CA Eide, SK Tantravahi, NA Vellore, J Estrada, FE Nicolini, ... Cancer cell 26 (3), 428-442, 2014 | 345 | 2014 |
| Impact of bone and liver metastases on patients with renal cell carcinoma treated with targeted therapy RR McKay, N Kroeger, W Xie, JL Lee, JJ Knox, GA Bjarnason, ... European urology 65 (3), 577-584, 2014 | 251 | 2014 |
| Combined STAT3 and BCR-ABL1 inhibition induces synthetic lethality in therapy-resistant chronic myeloid leukemia AM Eiring, BDG Page, IL Kraft, CC Mason, NA Vellore, D Resetca, ... Leukemia 29 (3), 586-597, 2015 | 144 | 2015 |
| Age-related mutations and chronic myelomonocytic leukemia CC Mason, JS Khorashad, SK Tantravahi, TW Kelley, MS Zabriskie, ... Leukemia 30 (4), 906-913, 2016 | 142 | 2016 |
| Addition of navitoclax to ongoing ruxolitinib therapy for patients with myelofibrosis with progression or suboptimal response: phase II safety and efficacy CN Harrison, JS Garcia, TCP Somervaille, JM Foran, S Verstovsek, ... Journal of Clinical Oncology 40 (15), 1671, 2022 | 78 | 2022 |
| Identification and prioritization of myeloid malignancy germline variants in a large cohort of adult patients with AML F Yang, N Long, T Anekpuritanang, D Bottomly, JC Savage, T Lee, ... Blood, The Journal of the American Society of Hematology 139 (8), 1208-1221, 2022 | 62 | 2022 |
| shRNA library screening identifies nucleocytoplasmic transport as a mediator of BCR-ABL1 kinase-independent resistance JS Khorashad, AM Eiring, CC Mason, KC Gantz, AD Bowler, HM Redwine, ... Blood, The Journal of the American Society of Hematology 125 (11), 1772-1781, 2015 | 49 | 2015 |
| Histiocytic neoplasms, version 2.2021, NCCN clinical practice guidelines in oncology RS Go, E Jacobsen, R Baiocchi, I Buhtoiarov, EB Butler, PK Campbell, ... Journal of the National Comprehensive Cancer Network 19 (11), 1277-1303, 2021 | 40 | 2021 |
| In vivo vaccination effect in multiple myeloma patients treated with the monoclonal antibody isatuximab D Atanackovic, S Yousef, C Shorter, SK Tantravahi, M Steinbach, ... Leukemia 34 (1), 317-321, 2020 | 36 | 2020 |
| Six-month progression-free survival as the primary endpoint to evaluate the activity of new agents as second-line therapy for advanced urothelial carcinoma N Agarwal, J Bellmunt, BL Maughan, KM Boucher, TK Choueiri, AQ Qu, ... Clinical genitourinary cancer 12 (2), 130-137, 2014 | 36 | 2014 |
| The transcriptome of CMML monocytes is highly inflammatory and reflects leukemia-specific and age-related alterations A Franzini, AD Pomicter, D Yan, JS Khorashad, SK Tantravahi, H Than, ... Blood Advances 3 (20), 2949-2961, 2019 | 33 | 2019 |
| Nuclear–cytoplasmic transport is a therapeutic target in myelofibrosis D Yan, AD Pomicter, S Tantravahi, CC Mason, AV Senina, JM Ahmann, ... Clinical Cancer Research 25 (7), 2323-2335, 2019 | 32 | 2019 |
| Addition of navitoclax to ongoing ruxolitinib treatment in patients with myelofibrosis (REFINE): a post-hoc analysis of molecular biomarkers in a phase 2 study N Pemmaraju, JS Garcia, J Potluri, JG Harb, Y Sun, P Jung, QQ Qin, ... The Lancet Haematology 9 (6), e434-e444, 2022 | 30 | 2022 |
| Correlation of degree of hypothyroidism with survival outcomes in patients with metastatic renal cell carcinoma receiving vascular endothelial growth factor receptor tyrosine … EB Bailey, SK Tantravahi, A Poole, AM Agarwal, AM Straubhar, JA Batten, ... Clinical Genitourinary Cancer 13 (3), e131-e137, 2015 | 28 | 2015 |
| A population-based overview of sequences of targeted therapy in metastatic renal cell carcinoma N Alimohamed, JL Lee, S Srinivas, GA Bjarnason, JJ Knox, MJ Mackenzie, ... Clinical genitourinary cancer 12 (4), e127-e131, 2014 | 28 | 2014 |
| A phase II study of the efficacy, safety, and determinants of response to 5-azacitidine (Vidaza®) in patients with chronic myelomonocytic leukemia SK Tantravahi, P Szankasi, JS Khorashad, KH Dao, T Kovacsovics, ... Leukemia & lymphoma 57 (10), 2441-2444, 2016 | 23 | 2016 |
| Incidence of severe nephrotoxicity with cisplatin based on renal function eligibility criteria: indirect comparison meta-analysis A Dahal, BK Bellows, G Sonpavde, SK Tantravahi, TK Choueiri, ... American Journal of Clinical Oncology 39 (5), 497-506, 2016 | 21 | 2016 |
| Extension of overall survival beyond objective responses in patients with metastatic renal cell carcinoma treated with high-dose interleukin-2 DD Stenehjem, M Toole, J Merriman, K Parikh, S Daignault, S Scarlett, ... Cancer Immunology, Immunotherapy 65, 941-949, 2016 | 19 | 2016 |
| Everolimus versus temsirolimus in metastatic renal cell carcinoma after progression with previous systemic therapies SB Patel, DD Stenehjem, DM Gill, SK Tantravahi, AM Agarwal, JA Hsu, ... Clinical Genitourinary Cancer 14 (2), 153-159, 2016 | 16 | 2016 |
| First-line Mammalian target of rapamycin inhibition in metastatic renal cell carcinoma: an analysis of practice patterns from the International Metastatic Renal Cell Carcinoma … LC Harshman, N Kroeger, SY Rha, F Donskov, L Wood, SK Tantravahi, ... Clinical genitourinary cancer 12 (5), 335-340, 2014 | 16 | 2014 |
